Search

Your search keyword '"Kong, Li Ren"' showing total 56 results
Start Over Author "Kong, Li Ren" Database Unpaywall
56 results on '"Kong, Li Ren"'

1. Insights from multi-omic modeling of neurodegeneration in xeroderma pigmentosum using an induced pluripotent stem cell system

Author

Badja, Cherif, primary, Momen, Sophie, additional, Koh, Gene Ching Chiek, additional, Boushaki, Soraya, additional, Roumeliotis, Theodoros I., additional, Kozik, Zuza, additional, Jones, Ian, additional, Bousgouni, Vicky, additional, Dias, João M.L., additional, Krokidis, Marios G., additional, Young, Jamie, additional, Chen, Hongwei, additional, Yang, Ming, additional, Docquier, France, additional, Memari, Yasin, additional, Valcarcel-Zimenez, Lorea, additional, Gupta, Komal, additional, Kong, Li Ren, additional, Fawcett, Heather, additional, Robert, Florian, additional, Zhao, Salome, additional, Degasperi, Andrea, additional, Kumar, Yogesh, additional, Davies, Helen, additional, Harris, Rebecca, additional, Frezza, Christian, additional, Chatgilialoglu, Chryssostomos, additional, Sarkany, Robert, additional, Lehmann, Alan, additional, Bakal, Chris, additional, Choudhary, Jyoti, additional, Fassihi, Hiva, additional, and Nik-Zainal, Serena, additional

Published
2024
Full Text
View/download PDF

2. A glycolytic metabolite bypasses “two-hit” tumor suppression by BRCA2

Author

Kong, Li Ren, primary, Gupta, Komal, additional, Wu, Andy Jialun, additional, Perera, David, additional, Ivanyi-Nagy, Roland, additional, Ahmed, Syed Moiz, additional, Tan, Tuan Zea, additional, Tan, Shawn Lu-Wen, additional, Fuddin, Alessandra, additional, Sundaramoorthy, Elayanambi, additional, Goh, Grace Shiqing, additional, Wong, Regina Tong Xin, additional, Costa, Ana S.H., additional, Oddy, Callum, additional, Wong, Hannan, additional, Patro, C. Pawan K., additional, Kho, Yun Suen, additional, Huang, Xiao Zi, additional, Choo, Joan, additional, Shehata, Mona, additional, Lee, Soo Chin, additional, Goh, Boon Cher, additional, Frezza, Christian, additional, Pitt, Jason J., additional, and Venkitaraman, Ashok R., additional

Published
2024
Full Text
View/download PDF

4. A rare genetic disorder provides insights into mechanisms of early-onset neurodegeneration

Author

Badja, Cherif, primary, Momen, Sophie, additional, Koh, Gene Ching Cheik, additional, Boushaki, Soraya, additional, Roumeliotis, Theodoros I., additional, Kozik, Zuza, additional, Jones, Ian, additional, Bousgouni, Vicky, additional, Dias, Joao M. L., additional, Krokidis, Marios, additional, Young, Jamie, additional, Chen, Hongwei, additional, Yang, Ming, additional, Docquier, France, additional, Memari, Yasin, additional, Valcarcel-Jimenez, Lorea, additional, Gupta, Komal, additional, Kong, Li Ren, additional, Fawcett, Heather, additional, Robert, Florian, additional, Zhao, Salome, additional, Degasperi, Andrea, additional, Davies, Helen, additional, Harris, Rebecca, additional, Frezza, Christian, additional, Chatgilialoglu, Chryssostomos, additional, Sarkany, Robert, additional, Lehmann, Alan, additional, Bakal, Chris, additional, Choudhary, Jyoti, additional, Fassihi, Hiva, additional, and Nik-Zainal, Serena, additional

Published
2023
Full Text
View/download PDF

5. Supplementary Figure S4 from MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma

Author

Kong, Li Ren, primary, Chua, Kian Ngiap, primary, Sim, Wen Jing, primary, Ng, Hsien Chun, primary, Bi, Chonglei, primary, Ho, Jingshan, primary, Nga, Min En, primary, Pang, Yin Huei, primary, Ong, Weijie Richard, primary, Soo, Ross Andrew, primary, Huynh, Hung, primary, Chng, Wee Joo, primary, Thiery, Jean-Paul, primary, and Goh, Boon Cher, primary

Published
2023
Full Text
View/download PDF

6. Supplementary Figure S8 from MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma

Author

Kong, Li Ren, primary, Chua, Kian Ngiap, primary, Sim, Wen Jing, primary, Ng, Hsien Chun, primary, Bi, Chonglei, primary, Ho, Jingshan, primary, Nga, Min En, primary, Pang, Yin Huei, primary, Ong, Weijie Richard, primary, Soo, Ross Andrew, primary, Huynh, Hung, primary, Chng, Wee Joo, primary, Thiery, Jean-Paul, primary, and Goh, Boon Cher, primary

Published
2023
Full Text
View/download PDF

7. Supplementary Figure S6 from MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma

Author

Kong, Li Ren, primary, Chua, Kian Ngiap, primary, Sim, Wen Jing, primary, Ng, Hsien Chun, primary, Bi, Chonglei, primary, Ho, Jingshan, primary, Nga, Min En, primary, Pang, Yin Huei, primary, Ong, Weijie Richard, primary, Soo, Ross Andrew, primary, Huynh, Hung, primary, Chng, Wee Joo, primary, Thiery, Jean-Paul, primary, and Goh, Boon Cher, primary

Published
2023
Full Text
View/download PDF

8. Supplementary Figure S2 from MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma

Author

Kong, Li Ren, primary, Chua, Kian Ngiap, primary, Sim, Wen Jing, primary, Ng, Hsien Chun, primary, Bi, Chonglei, primary, Ho, Jingshan, primary, Nga, Min En, primary, Pang, Yin Huei, primary, Ong, Weijie Richard, primary, Soo, Ross Andrew, primary, Huynh, Hung, primary, Chng, Wee Joo, primary, Thiery, Jean-Paul, primary, and Goh, Boon Cher, primary

Published
2023
Full Text
View/download PDF

9. Supplementary Figure S10 from MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma

Author

Kong, Li Ren, primary, Chua, Kian Ngiap, primary, Sim, Wen Jing, primary, Ng, Hsien Chun, primary, Bi, Chonglei, primary, Ho, Jingshan, primary, Nga, Min En, primary, Pang, Yin Huei, primary, Ong, Weijie Richard, primary, Soo, Ross Andrew, primary, Huynh, Hung, primary, Chng, Wee Joo, primary, Thiery, Jean-Paul, primary, and Goh, Boon Cher, primary

Published
2023
Full Text
View/download PDF

10. Supplementary Figure S1 from MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma

Author

Kong, Li Ren, primary, Chua, Kian Ngiap, primary, Sim, Wen Jing, primary, Ng, Hsien Chun, primary, Bi, Chonglei, primary, Ho, Jingshan, primary, Nga, Min En, primary, Pang, Yin Huei, primary, Ong, Weijie Richard, primary, Soo, Ross Andrew, primary, Huynh, Hung, primary, Chng, Wee Joo, primary, Thiery, Jean-Paul, primary, and Goh, Boon Cher, primary

Published
2023
Full Text
View/download PDF

11. Supplementary Figure S11 from MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma

Author

Kong, Li Ren, primary, Chua, Kian Ngiap, primary, Sim, Wen Jing, primary, Ng, Hsien Chun, primary, Bi, Chonglei, primary, Ho, Jingshan, primary, Nga, Min En, primary, Pang, Yin Huei, primary, Ong, Weijie Richard, primary, Soo, Ross Andrew, primary, Huynh, Hung, primary, Chng, Wee Joo, primary, Thiery, Jean-Paul, primary, and Goh, Boon Cher, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figure S3 from MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma

Author

Kong, Li Ren, primary, Chua, Kian Ngiap, primary, Sim, Wen Jing, primary, Ng, Hsien Chun, primary, Bi, Chonglei, primary, Ho, Jingshan, primary, Nga, Min En, primary, Pang, Yin Huei, primary, Ong, Weijie Richard, primary, Soo, Ross Andrew, primary, Huynh, Hung, primary, Chng, Wee Joo, primary, Thiery, Jean-Paul, primary, and Goh, Boon Cher, primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figure S3 from MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma

Author

Kong, Li Ren, primary, Chua, Kian Ngiap, primary, Sim, Wen Jing, primary, Ng, Hsien Chun, primary, Bi, Chonglei, primary, Ho, Jingshan, primary, Nga, Min En, primary, Pang, Yin Huei, primary, Ong, Weijie Richard, primary, Soo, Ross Andrew, primary, Huynh, Hung, primary, Chng, Wee Joo, primary, Thiery, Jean-Paul, primary, and Goh, Boon Cher, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure S4 from MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma

Author

Kong, Li Ren, primary, Chua, Kian Ngiap, primary, Sim, Wen Jing, primary, Ng, Hsien Chun, primary, Bi, Chonglei, primary, Ho, Jingshan, primary, Nga, Min En, primary, Pang, Yin Huei, primary, Ong, Weijie Richard, primary, Soo, Ross Andrew, primary, Huynh, Hung, primary, Chng, Wee Joo, primary, Thiery, Jean-Paul, primary, and Goh, Boon Cher, primary

Published
2023
Full Text
View/download PDF

15. Supplementary Figure S7 from MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma

Author

Kong, Li Ren, primary, Chua, Kian Ngiap, primary, Sim, Wen Jing, primary, Ng, Hsien Chun, primary, Bi, Chonglei, primary, Ho, Jingshan, primary, Nga, Min En, primary, Pang, Yin Huei, primary, Ong, Weijie Richard, primary, Soo, Ross Andrew, primary, Huynh, Hung, primary, Chng, Wee Joo, primary, Thiery, Jean-Paul, primary, and Goh, Boon Cher, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Text from MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma

Author

Kong, Li Ren, primary, Chua, Kian Ngiap, primary, Sim, Wen Jing, primary, Ng, Hsien Chun, primary, Bi, Chonglei, primary, Ho, Jingshan, primary, Nga, Min En, primary, Pang, Yin Huei, primary, Ong, Weijie Richard, primary, Soo, Ross Andrew, primary, Huynh, Hung, primary, Chng, Wee Joo, primary, Thiery, Jean-Paul, primary, and Goh, Boon Cher, primary

Published
2023
Full Text
View/download PDF

17. Supplementary Figure S8 from MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma

Author

Kong, Li Ren, primary, Chua, Kian Ngiap, primary, Sim, Wen Jing, primary, Ng, Hsien Chun, primary, Bi, Chonglei, primary, Ho, Jingshan, primary, Nga, Min En, primary, Pang, Yin Huei, primary, Ong, Weijie Richard, primary, Soo, Ross Andrew, primary, Huynh, Hung, primary, Chng, Wee Joo, primary, Thiery, Jean-Paul, primary, and Goh, Boon Cher, primary

Published
2023
Full Text
View/download PDF

18. Supplementary Figure S1 from MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma

Author

Kong, Li Ren, primary, Chua, Kian Ngiap, primary, Sim, Wen Jing, primary, Ng, Hsien Chun, primary, Bi, Chonglei, primary, Ho, Jingshan, primary, Nga, Min En, primary, Pang, Yin Huei, primary, Ong, Weijie Richard, primary, Soo, Ross Andrew, primary, Huynh, Hung, primary, Chng, Wee Joo, primary, Thiery, Jean-Paul, primary, and Goh, Boon Cher, primary

Published
2023
Full Text
View/download PDF

19. Data from MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma

Author

Kong, Li Ren, primary, Chua, Kian Ngiap, primary, Sim, Wen Jing, primary, Ng, Hsien Chun, primary, Bi, Chonglei, primary, Ho, Jingshan, primary, Nga, Min En, primary, Pang, Yin Huei, primary, Ong, Weijie Richard, primary, Soo, Ross Andrew, primary, Huynh, Hung, primary, Chng, Wee Joo, primary, Thiery, Jean-Paul, primary, and Goh, Boon Cher, primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figure S5 from MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma

Author

Kong, Li Ren, primary, Chua, Kian Ngiap, primary, Sim, Wen Jing, primary, Ng, Hsien Chun, primary, Bi, Chonglei, primary, Ho, Jingshan, primary, Nga, Min En, primary, Pang, Yin Huei, primary, Ong, Weijie Richard, primary, Soo, Ross Andrew, primary, Huynh, Hung, primary, Chng, Wee Joo, primary, Thiery, Jean-Paul, primary, and Goh, Boon Cher, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Figure S2 from MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma

Author

Kong, Li Ren, primary, Chua, Kian Ngiap, primary, Sim, Wen Jing, primary, Ng, Hsien Chun, primary, Bi, Chonglei, primary, Ho, Jingshan, primary, Nga, Min En, primary, Pang, Yin Huei, primary, Ong, Weijie Richard, primary, Soo, Ross Andrew, primary, Huynh, Hung, primary, Chng, Wee Joo, primary, Thiery, Jean-Paul, primary, and Goh, Boon Cher, primary

Published
2023
Full Text
View/download PDF

22. Supplementary Figure S7 from MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma

Author

Kong, Li Ren, primary, Chua, Kian Ngiap, primary, Sim, Wen Jing, primary, Ng, Hsien Chun, primary, Bi, Chonglei, primary, Ho, Jingshan, primary, Nga, Min En, primary, Pang, Yin Huei, primary, Ong, Weijie Richard, primary, Soo, Ross Andrew, primary, Huynh, Hung, primary, Chng, Wee Joo, primary, Thiery, Jean-Paul, primary, and Goh, Boon Cher, primary

Published
2023
Full Text
View/download PDF

23. Data from MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma

Author

Kong, Li Ren, primary, Chua, Kian Ngiap, primary, Sim, Wen Jing, primary, Ng, Hsien Chun, primary, Bi, Chonglei, primary, Ho, Jingshan, primary, Nga, Min En, primary, Pang, Yin Huei, primary, Ong, Weijie Richard, primary, Soo, Ross Andrew, primary, Huynh, Hung, primary, Chng, Wee Joo, primary, Thiery, Jean-Paul, primary, and Goh, Boon Cher, primary

Published
2023
Full Text
View/download PDF

24. Supplementary Figure S9 from MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma

Author

Kong, Li Ren, primary, Chua, Kian Ngiap, primary, Sim, Wen Jing, primary, Ng, Hsien Chun, primary, Bi, Chonglei, primary, Ho, Jingshan, primary, Nga, Min En, primary, Pang, Yin Huei, primary, Ong, Weijie Richard, primary, Soo, Ross Andrew, primary, Huynh, Hung, primary, Chng, Wee Joo, primary, Thiery, Jean-Paul, primary, and Goh, Boon Cher, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Figure S5 from MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma

Author

Kong, Li Ren, primary, Chua, Kian Ngiap, primary, Sim, Wen Jing, primary, Ng, Hsien Chun, primary, Bi, Chonglei, primary, Ho, Jingshan, primary, Nga, Min En, primary, Pang, Yin Huei, primary, Ong, Weijie Richard, primary, Soo, Ross Andrew, primary, Huynh, Hung, primary, Chng, Wee Joo, primary, Thiery, Jean-Paul, primary, and Goh, Boon Cher, primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figure S11 from MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma

Author

Kong, Li Ren, primary, Chua, Kian Ngiap, primary, Sim, Wen Jing, primary, Ng, Hsien Chun, primary, Bi, Chonglei, primary, Ho, Jingshan, primary, Nga, Min En, primary, Pang, Yin Huei, primary, Ong, Weijie Richard, primary, Soo, Ross Andrew, primary, Huynh, Hung, primary, Chng, Wee Joo, primary, Thiery, Jean-Paul, primary, and Goh, Boon Cher, primary

Published
2023
Full Text
View/download PDF

27. Supplementary Figure S10 from MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma

Author

Kong, Li Ren, primary, Chua, Kian Ngiap, primary, Sim, Wen Jing, primary, Ng, Hsien Chun, primary, Bi, Chonglei, primary, Ho, Jingshan, primary, Nga, Min En, primary, Pang, Yin Huei, primary, Ong, Weijie Richard, primary, Soo, Ross Andrew, primary, Huynh, Hung, primary, Chng, Wee Joo, primary, Thiery, Jean-Paul, primary, and Goh, Boon Cher, primary

Published
2023
Full Text
View/download PDF

28. Supplementary Figure S9 from MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma

Author

Kong, Li Ren, primary, Chua, Kian Ngiap, primary, Sim, Wen Jing, primary, Ng, Hsien Chun, primary, Bi, Chonglei, primary, Ho, Jingshan, primary, Nga, Min En, primary, Pang, Yin Huei, primary, Ong, Weijie Richard, primary, Soo, Ross Andrew, primary, Huynh, Hung, primary, Chng, Wee Joo, primary, Thiery, Jean-Paul, primary, and Goh, Boon Cher, primary

Published
2023
Full Text
View/download PDF

29. Supplementary Figure S6 from MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma

Author

Kong, Li Ren, primary, Chua, Kian Ngiap, primary, Sim, Wen Jing, primary, Ng, Hsien Chun, primary, Bi, Chonglei, primary, Ho, Jingshan, primary, Nga, Min En, primary, Pang, Yin Huei, primary, Ong, Weijie Richard, primary, Soo, Ross Andrew, primary, Huynh, Hung, primary, Chng, Wee Joo, primary, Thiery, Jean-Paul, primary, and Goh, Boon Cher, primary

Published
2023
Full Text
View/download PDF

30. Supplementary Text from MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma

Author

Kong, Li Ren, primary, Chua, Kian Ngiap, primary, Sim, Wen Jing, primary, Ng, Hsien Chun, primary, Bi, Chonglei, primary, Ho, Jingshan, primary, Nga, Min En, primary, Pang, Yin Huei, primary, Ong, Weijie Richard, primary, Soo, Ross Andrew, primary, Huynh, Hung, primary, Chng, Wee Joo, primary, Thiery, Jean-Paul, primary, and Goh, Boon Cher, primary

Published
2023
Full Text
View/download PDF

31. FAM3C in circulating tumor-derived extracellular vesicles promotes non-small cell lung cancer growth in secondary sites

Author

Thuya, Win Lwin, primary, Kong, Li Ren, additional, Syn, Nicholas L., additional, Ding, Ling-Wen, additional, Cheow, Esther Sok Hwee, additional, Wong, Regina Tong Xin, additional, Wang, Tingting, additional, Goh, Robby Miguel Wen-Jing, additional, Song, Hongyan, additional, Jayasinghe, Migara K., additional, Le, Minh TN, additional, Hu, Jian Cheng, additional, Yong, Wei-Peng, additional, Lee, Soo-Chin, additional, Wong, Andrea Li-Ann, additional, Sethi, Gautam, additional, Hung, Huynh The, additional, Ho, Paul Chi-Lui, additional, Thiery, Jean-Paul, additional, Sze, Siu Kwan, additional, Guo, Tiannan, additional, Soo, Ross A., additional, Yang, Henry, additional, Lim, Yaw Chyn, additional, Wang, Lingzhi, additional, and Goh, Boon-Cher, additional

Published
2023
Full Text
View/download PDF

35. DUSP16 promotes cancer chemoresistance through regulation of mitochondria-mediated cell death

Author

Low, Heng Boon, primary, Wong, Zhen Lim, additional, Wu, Bangyuan, additional, Kong, Li Ren, additional, Png, Chin Wen, additional, Cho, Yik-Lam, additional, Li, Chun-Wei, additional, Xiao, Fengchun, additional, Xin, Xuan, additional, Yang, Henry, additional, Loo, Jia Min, additional, Lee, Fiona Yi Xin, additional, Tan, Iain Bee Huat, additional, DasGupta, Ramanuj, additional, Shen, Han-Ming, additional, Schwarz, Herbert, additional, Gascoigne, Nicholas R. J., additional, Goh, Boon Cher, additional, Xu, Xiaohong, additional, and Zhang, Yongliang, additional

Published
2021
Full Text
View/download PDF

37. Integration of Antiangiogenic Therapy with Cisplatin and Gemcitabine Chemotherapy in Patients with Nasopharyngeal Carcinoma

Author

Chong, Wan Qin, primary, Lim, Chwee Ming, additional, Sinha, Arvind Kumar, additional, Tan, Chee Seng, additional, Chan, Gloria Hui Jia, additional, Huang, Yiqing, additional, Kumarakulasinghe, Nesaretnam Barr, additional, Sundar, Raghav, additional, Jeyasekharan, Anand D., additional, Loh, Woei Shyang, additional, Tay, Joshua K., additional, Yadav, Kritika, additional, Wang, Lingzhi, additional, Wong, Andrea L., additional, Kong, Li Ren, additional, Soo, Ross Andrew, additional, Lau, Jieying Amelia, additional, Soon, Yu Yang, additional, Goh, Robby Miguel, additional, Ho, Francis Cho Hao, additional, Chong, Siew Meng, additional, Lee, Soo Chin, additional, Loh, Kwok Seng, additional, Tai, Bee Choo, additional, Lim, Yaw Chyn, additional, and Goh, Boon Cher, additional

Published
2020
Full Text
View/download PDF

38. Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation

Author

Kong, Li Ren, primary, Ong, Richard Weijie, additional, Tan, Tuan Zea, additional, Mohamed Salleh, Nur Afiqah Binte, additional, Thangavelu, Matan, additional, Chan, Jane Vin, additional, Koh, Lie Yong Judice, additional, Periyasamy, Giridharan, additional, Lau, Jieying Amelia, additional, Le, Thi Bich Uyen, additional, Wang, Lingzhi, additional, Lee, Miyoung, additional, Kannan, Srinivasaraghavan, additional, Verma, Chandra S., additional, Lim, Chwee Ming, additional, Chng, Wee Joo, additional, Lane, David P., additional, Venkitaraman, Ashok, additional, Hung, Huynh The, additional, Cheok, Chit Fang, additional, and Goh, Boon Cher, additional

Published
2020
Full Text
View/download PDF

39. A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinoma

Author

Kong, Li Ren, primary, Mohamed Salleh, Nur Afiqah Binte, additional, Ong, Richard Weijie, additional, Tan, Tuan Zea, additional, Syn, Nicholas L., additional, Goh, Robby Miguel, additional, Fhu, Chee Wai, additional, Tan, Daniel S. W., additional, Iyer, N. Gopalakrishna, additional, Kannan, Srinivasaraghavan, additional, Verma, Chandra S., additional, Lim, Yaw Chyn, additional, Soo, Ross, additional, Ho, Jingshan, additional, Huang, Yiqing, additional, Lim, Joline S. J., additional, Yan, Benedict Junrong, additional, Nga, Min En, additional, Lim, Seng Gee, additional, Koeffler, H. Phillip, additional, Lee, Soo Chin, additional, Kappei, Dennis, additional, Hung, Huynh The, additional, and Goh, Boon Cher, additional

Published
2020
Full Text
View/download PDF

41. A Common Met Polymorphism Harnesses Her2 Signaling to Drive Aggressive Squamous Cell Carcinoma

Author

Kong, Li Ren, primary, Salleh, Nur Afiqah Binte Mohamed, additional, Ong, Richard Weijie, additional, Tan, Tuan Zea, additional, Syn, Nicholas L., additional, Goh, Robby Miguel, additional, Tan, Daniel S. W., additional, Iyer, N. Gopalakrishna, additional, Lim, Yaw Chyn, additional, Soo, Ross, additional, Ho, Jingshan, additional, Huang, Yiqing, additional, Lim, Joline S. J., additional, Yan, Benedict Junrong, additional, Nga, Min En, additional, Lim, Seng Gee, additional, Koeffler, H. Phillip, additional, Lee, Soo Chin, additional, Kappei, Dennis, additional, Hung, Huynh The, additional, and Goh, Boon Cher, additional

Published
2019
Full Text
View/download PDF

44. A novel combinatorial strategy using Seliciclib® and Belinostat® for eradication of non-small cell lung cancer via apoptosis induction and BID activation

Author

Ong, Pei-Shi, primary, Wang, Lingzhi, additional, Chia, Deborah Miao-Hui, additional, Seah, Jolyn Yu-Xin, additional, Kong, Li-Ren, additional, Thuya, Win-Lwin, additional, Chinnathambi, Arunachalam, additional, Lau, Jie-Ying Amelia, additional, Wong, Andrea Li-Ann, additional, Yong, Wei-Peng, additional, Yang, Daiwen, additional, Ho, Paul Chi-Lui, additional, Sethi, Gautam, additional, and Goh, Boon-Cher, additional

Published
2016
Full Text
View/download PDF

47. MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma

Author

Kong, Li Ren, primary, Chua, Kian Ngiap, additional, Sim, Wen Jing, additional, Ng, Hsien Chun, additional, Bi, Chonglei, additional, Ho, Jingshan, additional, Nga, Min En, additional, Pang, Yin Huei, additional, Ong, Weijie Richard, additional, Soo, Ross Andrew, additional, Huynh, Hung, additional, Chng, Wee Joo, additional, Thiery, Jean-Paul, additional, and Goh, Boon Cher, additional

Published
2015
Full Text
View/download PDF

49. Extended cohort study of OPB51602, a novel inhibitor of STAT3/5 activation, in non-small cell lung carcinoma.

Author

Lim, Joline Si Jing, primary, Wong, Andrea Li Ann, additional, Soo, Ross A., additional, Lee, Soo-Chin, additional, Marban, Patrick, additional, Kong, Li Ren, additional, Pang, Brendan, additional, Soong, Richie Chuan Teck, additional, Tan, Daniel Shao-Weng, additional, Tan, David Shao Peng, additional, Higuchi, Kumi, additional, Motoyama, Masaaki, additional, Tsunoda, Takeshi, additional, and Goh, Boon C., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results